Study: Identifying Optimal Points of Intervention to Address Racial and Ethnic Disparities in COVID-19 Fatality Rates in New York State

University at Albany, State University of New York

Newswise — ALBANY, N.Y. (July 1, 2020) – Results from a new COVID-19 epidemiological study have been released from the University at Albany in partnership with the New York State Department of Health (NYSDOH); the findings were published today in the peer-reviewed journal, Annals of Epidemiology.

The study aimed to answer three main questions:

  1. What are the most informative ways to measure fatalities rates across racial and ethnic communities in New York State, and what do these different measures tell us about health disparities?
  2. Do publicly available data for the state allow for the construction of a COVID-19 outcomes continuum so that population size, rate of SARS-CoV-2 infection, rate of diagnosis of infection, hospitalization and fatality can be meaningfully expressed in one comprehensive figure?
  3. Can such a continuum be constructed separately for racial and ethnic minority communities in New York and, if so, what lessons can be learned about how to best intervene to address apparent health disparities in fatality rates?

Analyses published in the paper found the following:

  • Estimated per-population COVID-19 fatality rates (deaths divided by population size) were 0.03%, 0.18% and 0.12% for white non-Hispanic, Black non-Hispanic and Hispanic adults. Estimated infection fatality rates (deaths divided by infections in a particular racial or ethnic community) were 0.42%, 0.96% and 0.41% for white non-Hispanic, Black non-Hispanic and Hispanic adults. Estimated case fatality rates (deaths divided by diagnosed cases) were 3.57%, 9.46% and 6.25% for white non-Hispanic, Black non-Hispanic and Hispanic adults.
  • The percentage of each population experiencing SARS-CoV-2 infection was 8.0%, 18.7% and 28.4% for white non-Hispanic, Black non-Hispanic and Hispanic adults.
  • The percentage of persons experiencing infection who were ultimately hospitalized was 1.4%, 2.7% and 1.7% for white, non-Hispanic, Black non-Hispanic and Hispanic adults.
  • The fraction of hospitalized patients who ultimately died was estimated to be 30.2%, 35.8% and 23.9% for white non-Hispanic, Black non-Hispanic and Hispanic adults.
  • Examination of these and other disparities across the outcomes continuum by racial and ethnic category suggested that health disparities in fatalities for Hispanic communities relative to white are best explained by differences in infection rates. For non-Hispanic Black adults, relative to white, the disparity in fatalities was primarily driven by differences in both infection-experience and in the need for hospitalization, given infection. (For illustration, please see Table below.)
  • These findings suggest potentially effective points in the continuum to intervention with policies and programs designed to alleviate COVID-19 morbidity and mortality, and the disparities therein; it is especially important to intervene to prevent SARS-CoV-2 infections in the first place, and to do so will require addressing the societal determinants and root causes of these infections.

David Holtgrave, dean of the School of Public Health at University at Albany, said “COVID-19 fatality differences in Latinx and Black communities, relative to white communities, are clear. Our new analysis helps to understand some of the key drivers of these disparities and suggests ways to construct policies and programs to both improve public health and social justice. It is most important to construct policies and programs that address the upstream social determinants of SARS-CoV-2 infection in the first place, rather than wait to intervene near the point of fatality; by then it is too late to prevent and alleviate these disparities.”

For 35 years, UAlbany’s School of Public Health has partnered with NYSDOH on a variety of initiatives, and assisting the Department with the response for a health crisis of the magnitude of the COVID-19 pandemic is a natural fit.

Details on the full study are available at the Annals of Epidemiology website:

Illustration of Racial and Ethnic Health Disparities in the COVID-19 Outcome Continuum,

New York State, as of March 29, 2020

(Numbers are estimates based on currently best available data, and taken from article’s Fig. 1)



Racial and Ethnic Community

Population Size

(for illustration set to 10,000 persons per community)



SARS-CoV-2 Infections










White non-Hispanic






Black non-Hispanic
















Filters close

Showing results

110 of 2814
Newswise:Video Embedded uab-department-of-pathology-develops-strategy-to-support-guidesafe-entry-testing-process-more-than-200-000-samples
Released: 5-Aug-2020 4:10 PM EDT
UAB Department of Pathology develops strategy to support GuideSafe™ Entry Testing, process more than 200,000 samples
University of Alabama at Birmingham

This strategy will allow for ramping up testing capacity tenfold for the next 20-plus days leading up to the start of school.

Newswise: 239458_web.jpg
Released: 5-Aug-2020 2:50 PM EDT
New findings on enzymes with important role in SARS-CoV-2 infection
Uppsala University

Researchers at Uppsala University have described the presence, throughout the human body, of the enzyme ACE2.

Newswise: Button Project Lets Children See the Faces Behind the Masks
Released: 5-Aug-2020 2:50 PM EDT
Button Project Lets Children See the Faces Behind the Masks
Vanderbilt University Medical Center

When COVID-19 cases began rising in Nashville, masking became a regular part of life across Vanderbilt University Medical Center and Children’s Hospital as one of several public health safety measures to protect employees and patients from potential COVID-19 exposure. Children’s Hospital decided to get creative to ensure that the 1,700 children and families who visit the hospital and clinics each day can see that the same friendly faces they’ve always known still exist behind the masks.

Newswise: 239490_web.jpg
Released: 5-Aug-2020 1:45 PM EDT
Massey scientist suggests COVID-19 should be treated as an acute inflammatory disease
Virginia Commonwealth University (VCU)

The COVID-19 pandemic has had detrimental effects on global infrastructure sectors, including economic, political, health care, education and research systems, and there is still no definitive treatment strategy for the disease.

Newswise: Helping protect medical professionals
Released: 5-Aug-2020 1:05 PM EDT
Helping protect medical professionals
Sandia National Laboratories

A media comprised of a sandwich of materials, tested by Sandia National Laboratories, is being manufactured into N95-like respirators that could be used in local medical facilities. The project originated from the urgent need for personal protective equipment when the COVID-19 outbreak began.

Released: 5-Aug-2020 12:50 PM EDT
UCI scientists get ‘initial hit’ in developing drug to treat COVID-19
University of California, Irvine

Irvine, Calif., Aug. 5, 2020 – When the coronavirus pandemic hit, almost everyone at the University of California, Irvine – and colleges across the nation – had to abandon campus. But James Nowick, professor of chemistry, was not a part of that exodus. That’s because his lab, which designs and constructs chemical molecules, had the right equipment to help in the global push to find treatments for COVID-19.

access_time Embargo lifts in 2 days
Embargo will expire: 6-Aug-2020 11:00 AM EDT Released to reporters: 5-Aug-2020 12:40 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 6-Aug-2020 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Imitation May Be a Sincere Form of Treatment
Released: 5-Aug-2020 12:35 PM EDT
Imitation May Be a Sincere Form of Treatment
University of California San Diego Health

The National Institutes of Health will soon launch a phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.

Showing results

110 of 2814